

FRONT

150 mm

Package leaflet: Information for the patient
Combogesic 500 mg/150 mg film-coated tablets
Paracetamol and Ibuprofen

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you.

- Keep this leaflet. You may need to read it again.
- Ask your pharmacist if you need more information or advice.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
- You must talk to a doctor if you do not feel better or if you feel worse after 3 days.
- You should not take this product for longer than 3 days.

This medicine is available without prescription. However, you still need to read this leaflet carefully to get the best results from it.

What is in this leaflet

1. What Combogesic is and what it is used for
2. What you need to know before you take Combogesic
3. How to take Combogesic
4. Possible side effects
5. How to store Combogesic
6. Contents of the pack and other information

1. What Combogesic is and what it is used for

Combogesic contains paracetamol and ibuprofen.

Paracetamol works to stop the pain messages from getting through to the brain. It also acts to reduce fever. Ibuprofen belongs to a group of medicines called non-steroidal anti-inflammatory drugs (or NSAIDs). It relieves pain and reduces inflammation (swelling, redness or soreness).

Combogesic is used for temporary relief of pain associated with:

- headache
- migraine
- backache
- period pain
- dental pain
- muscular pain
- cold and flu symptoms
- sore throat
- fever

Ask your doctor or pharmacist if you have any questions about this medicine.

You must talk to a doctor if you do not feel better or if you feel worse after 3 days.

2. What you need to know before you take Combogesic

Do not take Combogesic:

- if you are allergic to the active substance(s) or any of the other ingredients of this medicine (listed in section 6);
- if you are (or have previously) bled from the rectum (back passage), have black sticky bowel motions (stools) or bloody diarrhoea;
- if you have a peptic ulcer (i.e. stomach or duodenal ulcer), a recent history of one, or have had peptic ulcers before;
- with any other medicines containing paracetamol or ibuprofen
- if you regularly drink large quantities of alcohol
- if you have severe heart failure, hepatic failure or renal failure
- if you have cerebrovascular or other active bleeding
- if you have blood-formation disturbances, i.e. reduced numbers of platelets in the blood
- if you have asthma, urticaria or allergic-type reactions after taking aspirin, or other NSAIDs
- during the last three months of pregnancy

Warnings and precautions

Talk to your doctor or pharmacist before taking Combogesic.

If you are taking Combogesic for longer than the recommended time or at higher than recommended doses you are at risk of serious harms. These include serious harms to the stomach/gut and kidneys, as well as very low levels of potassium in your blood. These can be fatal (see section 4).

Talk to your doctor or pharmacist if you have an infection - please see heading "Infections" below.

Anti-inflammatory/pain-killer medicines like ibuprofen may be associated with a small increased risk of heart attack or stroke, particularly when used at high doses. Do not exceed the recommended dose or duration of treatment.

Skin reactions

Serious skin reactions have been reported in association with Combogesic treatment. You should stop taking Combogesic and seek medical attention immediately, if you develop any skin rash, lesions of the mucous membranes, blisters or other signs of allergy since this can be the first signs of a very serious skin reaction. See Section 4.

Infections

Combogesic may hide signs of infections such as fever and pain. It is therefore possible that Combogesic may delay appropriate treatment of infection, which may lead to an increased risk of complications. This has been observed in pneumonia caused by bacteria and bacterial skin infections related to chickenpox. If you take this medicine while you have an infection and your symptoms of the infection persist or worsen, consult a doctor without delay.

You should discuss your treatment with your doctor or pharmacist before taking Combogesic if you:

- have heart problems including heart failure, angina (chest pain), or if you have had a heart attack, bypass surgery, peripheral artery disease (poor circulation in the legs or feet due to narrow or blocked arteries), or any kind of stroke (including 'mini-stroke' or transient ischaemic attack "TIA");
- have high blood pressure, diabetes, high cholesterol, have a family history of heart disease or stroke, or if you are a smoker.
- have liver disease, hepatitis, kidney disease or difficulty urinating;
- are a heavy drinker or drug user;
- have allergies to any other medicines containing aspirin, or other NSAID medicines or any other substances listed at the end of this leaflet;
- are pregnant or intend to become pregnant;
- are breast-feeding or plan to breast-feed;
- currently have an infection;
- plan to have surgery;
- have or have had other medical conditions including:
 - > heartburn, indigestion, stomach ulcer or any other stomach problems;
 - > vomiting blood or bleeding from back passage;
 - > asthma;
 - > vision problems;
 - > tendency to bleed or other blood problems;
 - > bowel or intestinal problems such as ulcerative colitis or Crohn's Disease
 - > swelling of ankles or feet;
 - > diarrhoea;
 - > inherited genetic or acquired disorder of certain enzymes that manifest with either neurological complications or skin problems or occasionally both i.e. porphyria;
 - > smallpox;
 - > autoimmune disease such as Lupus erythematosus.

Do not drink alcoholic beverages when taking this medication. Combining alcohol with Combogesic may lead to liver damage.

The product belongs to a group of medicines (NSAIDs) which may impair the fertility in women. This effect is reversible on stopping the medicine. Taking Combogesic may interfere with the results from the urine analysis test for 5-hydroxyindoleacetic acid (5HIAA), causing false-positive results. To avoid false results do not take Combogesic or other paracetamol containing products for several hours before or during the collection of the urine specimen.

Children and adolescents

This product is not recommended for children under 18 years.

Other medicines and Combogesic

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Combogesic may affect or be affected by some other medicines. For example:-

- medicines that are anti-coagulants (i.e. thin blood/prevent clotting e.g. aspirin, warfarin, ticlopidine)
- medicines to treat epilepsy or fits such as phenytoin
- chloramphenicol, an antibiotic used to treat ear and eye infections
- probenecid, a medicine used to treat gout
- zidovudine, a medicine used to treat HIV (the virus that causes acquired immunodeficiency disease)
- medicines used to treat tuberculosis such as isoniazid
- aspirin, salicylates or other NSAID medicines
- medicines that reduce high blood pressure (ACE-inhibitors such as captopril, beta-blockers such as atenolol medicines, angiotensin-II receptor antagonists such as losartan)
- medicines for other heart conditions such as digoxin
- diuretics, also called fluid tablets
- lithium, a medicine used to treat some types of depression
- methotrexate, a medicine used to treat arthritis and some types of cancer
- corticosteroids, such as prednisone, cortisone
- metoclopramide, propantheline
- tacrolimus or ciclosporin, immunosuppressive drugs used after organ transplant
- sulphonylureas, a medicine used to treat diabetes
- some antibiotics (such as quinolone antibiotics)
- flucloxacillin (antibiotic), due to a serious risk of blood and fluid abnormality (high anion gap metabolic acidosis) that must have urgent treatment and which may occur particularly in case of severe renal impairment, sepsis (when bacteria and their toxins circulate in the blood leading to organ damage), malnutrition, chronic alcoholism, and if the maximum daily doses of paracetamol are used.

These medicines may be affected by Combogesic or may affect how well Combogesic works. You may need different amounts of your medicines, or you may need to take different medicines.

Some other medicines may also affect or be affected by the treatment with Combogesic. You should therefore always seek the advice of your doctor or pharmacist before you use Combogesic with other medicines.

Your doctor and pharmacist will have more information on these and other medicines to be careful with or avoid while taking this medicine.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Do not take this medicine during the last 3 months of your pregnancy as it could harm your unborn child or cause problems at delivery. It can cause kidney and heart problems in your unborn baby. It may affect your and your baby's tendency to bleed and cause labour to be later or longer than expected.




You should not take Combogesic during the first 6 months of pregnancy unless absolutely necessary and advised by your doctor. If you need treatment during this period or while you are trying to get pregnant, the lowest dose for the shortest time possible should be used. If taken more than a few days from 20 weeks of pregnancy onward, Combogesic can cause kidney problems in your inborn baby that may lead to low levels of amniotic fluid that surrounds the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the heart of the baby. If you need treatment for longer than a few days, your doctor may recommend additional monitoring.

This product may impair female fertility and is not recommended in women attempting to conceive.

580 mm

Pranita Graphics

Sigma Laboratories Pvt. Ltd.		
Product Name	Combogesic 500mg/150mg film coated Tab	Pharma Code: 30569
Pack Size	NA	
Type	Package Insert	
Dimensions	580(L) x 150(W) mm	
Board	40 gsm bible paper	
Colours	■ Black	
Artwork Code No	PM000796-00	Superseded Artwork No. : Nil
Date	25.10.2023	Country : UK

Packaging Development Department	Site QA	Regulatory Affairs (Contract Giver)
Prepared by	Approved by	
		
Reason for Change : New artwork		

BACK

150 mm

49 mm	20 mm	25 mm	49 mm	49 mm	116 mm
-------	-------	-------	-------	-------	--------

Driving and using machines
Be careful driving or operating machines until you know how Combogesic affects you.

Combogesic contains Lactose Monohydrate:
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

Sodium content
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

3. How to take Combogesic
Always take this medicine exactly as your doctor or pharmacist has told you. These directions may differ from the information contained in this leaflet. Check with your doctor or pharmacist if you are not sure. **Do not take for more than 3 days.**

The lowest effective dose should be used for the shortest duration necessary to relieve symptoms. If you have an infection, consult a doctor without delay if symptoms (such as fever and pain) persist or worsen (see section 2).

The recommended dose is:

Adults: The usual dosage is one to two tablets taken every six hours, as required up to a maximum of six in 24 hours.

Use the lowest effective dose for the shortest time necessary to relieve symptoms. The patient should consult a doctor if the symptoms persist or worsen or if the product is required for more than 3 days.

Do not take more than 6 tablets in a 24 hour period.
If your doctor prescribes a different dose, follow directions given by your doctor.

Take Combogesic tablets with a full glass of water. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Use in children under 18 years
Combogesic is not recommended for children under 18 years.

If you take more Combogesic than you should
If you have taken more Combogesic than you should, or if children have taken this medicine by accident always contact a doctor or nearest hospital to get an opinion of the risk and advice on action to be taken. Do this even if there are no signs of discomfort or poisoning.

Taking too many Combogesic tablets can lead to delayed, serious liver and renal damage. You may need urgent medical attention

The symptoms can include nausea, stomach pain, vomiting (may be blood streaked), headache, ringing in the ears, confusion and shaky eye movement. At high doses, drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness and dizziness, blood in urine, cold body feeling, and breathing problems have been reported.

If you forget to take Combogesic
If it is almost time for your next dose, skip the missed dose and take your next dose when you are meant to. Otherwise, take it as soon as you remember, and then go back to taking your tablets as you would normally.
Do not take a double dose to make up for a forgotten dose.
If you are not sure whether to skip the dose, talk to your doctor or pharmacist.

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you get any side effects, talk to your doctor or pharmacist.

If any of these serious side effects happen, stop taking Combogesic and tell your doctor immediately or go to the emergency room at your nearest hospital:

- vomiting blood or material that looks like coffee grounds;
- bleeding from the back passage, black sticky bowel motions (stools) or bloody diarrhoea;
- swelling of the face, lips or tongue which may cause difficulty in swallowing or breathing;
- asthma, wheezing, shortness of breath;
- very rare cases of serious skin reactions have been reported including sudden or severe itching, skin rash, hives;
- severe blisters and bleeding in the lips, eyes, mouth, nose and genitals (Stevens-Johnson Syndrome)
- a severe skin reaction known as DRESS syndrome can occur. Symptoms of DRESS include: skin rash, fever, swelling of lymph nodes and an increase of eosinophils (a type of white blood cells).
- fever, generally feeling unwell, nausea, stomach ache, headache and stiff neck.

Combogesic, especially when taken at higher than recommended doses or for a prolonged period of time, can cause damage to your kidneys and affect them removing acids properly from your blood into the urine (renal tubular acidosis). It can also cause very low levels of potassium in your blood (see section 2). This is a very serious condition and will require immediate treatment. Signs and symptoms include muscle weakness and light-headedness.

Other side effects:

Common (may affect up to 1 in 10 people):

- fluid retention, swelling
- ringing in the ears (tinnitus)
- nausea or vomiting
- loss of appetite
- heartburn or pain in the upper part of your stomach
- diarrhoea
- skin rashes
- headache
- dizziness
- change in liver or kidney function (established by blood tests)

Uncommon (may affect up to 1 in 100 people):

- reduction in red blood cell numbers, bleeding episodes such as nosebleeds, abnormal or prolonged bleeding during menstrual periods, increased number of platelets
- eye problems such as blurred or diminished vision, changes to the appearance of colours
- wind and constipation.
- increased sensitivity to allergic reactions, angioedema (symptoms may include itchy, sore red eyes)
- breast enlargement (in males)
- abnormally low blood sugar (hypoglycaemia)
- change in mood, for example, depression, confusion, excessive emotional reactions
- change in the desire to sleep (sleepiness or sleeplessness)
- difficulty urinating
- thickening of respiratory secretions (mucous)

Rare (may affect up to 1 in 1,000 people):

- hallucinations and increased nightmare occurrence
- numbness or abnormal skin sensations (e.g. burning, tingling or pricking) in the hands and feet

Very rare (may affect up to 1 in 10,000 people):

- severe pain or tenderness in the stomach
- signs of frequent or worrying infections such as fever, severe chills, sore throat or mouth ulcers
- bleeding or bruising more easily than normal, reddish or purplish blotches under the skin
- signs of anaemia, such as tiredness, headaches, being short of breath, and looking pale
- vertigo
- yellowing of the skin and /or eyes, also called jaundice
- unusual weight gain, swelling of ankles or legs, decreased urine output
- involuntary muscle movements/spasms, tremors and convulsions, slowing of physical and emotional reactions
- temporary vision loss, pain during eye movements
- symptoms of sunburn (such as redness, itching, swelling, blistering) which may occur more quickly than normal
- fast or irregular heartbeats, also called palpitations
- increased sweating

Frequency not known

- A red, scaly widespread rash with bumps under the skin and blisters mainly localized on the skin folds, trunk, and upper extremities accompanied by fever at the initiation of treatment (acute generalised exanthematous pustulosis). Stop using Combogesic if you develop these symptoms and seek medical attention immediately. See also Section 2.

The above list includes serious side effects that may require medical attention. Serious side effects are rare for low doses of this medicine and when used for a short period of time.

Reporting of side effects
If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Combogesic
Keep this medicine out of the sight and reach of children.

Store below 30°C. Store in the original packaging to protect from light.

Do not use this medicine after the expiry date which is stated on the carton label and on the blister after EXP. The expiry date refers to the last day of that month.

Do not use this medicine if you notice packaging is torn or shows signs of tampering.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Combogesic contains
The active substances are paracetamol and ibuprofen.
The other ingredients are: maize starch, pregelatinised maize starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, talc, hypromellose (E464), lactose monohydrate, titanium dioxide (E171), macrogol/ PEG- 4000 and sodium citrate dihydrate (E331).

What Combogesic looks like and contents of the pack
Combogesic film-coated tablets are white coloured, capsule shaped 19 mm in length filmcoated tablets with break-line on one side and plain on the other side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Each blister pack contains 8, 10, 16, 20, 24, 30 and 32, film-coated tablets. Not all pack sizes may be marketed.

Marketing Authorisation Holder
Ceuta Healthcare Ltd, Hill House, 41 Richmond Hill, Bournemouth, Dorset, BH2 6HS, UK.




Manufacturer
QP-Services UK Ltd., 46 High Street, Yatton, Bristol, BS49 4HJ, UK
or
Elara Pharmservices Ltd., Iron Farm, 7 Grimesgate, Diseworth, Derby, DE74 2QD, UK.

This leaflet was last revised in October 2023. PM000796-00

PL 16243/0004

Pranita Graphics

Sigma Laboratories Pvt. Ltd.		
Product Name	Combogesic 500mg/150mg film coated Tab	Pharma Code: 30569
Pack Size	NA	
Type	Package Insert	
Dimensions	580(L) x 150(W) mm	
Board	40 gsm bible paper	
Colours	Black	
Artwork Code No	PM000796-00	Superseded Artwork No. : Nil
Date	25.10.2023	Country : UK

Packaging Development Department	Site QA	Regulatory Affairs (Contract Giver)
Prepared by	Approved by	
		
31/10/2023		
Reason for Change : New artwork		

Certificate Of Completion

Envelope Id: 6FC25DBE30C4415895B3AE8B59105987	Status: Completed
Subject: Complete with DocuSign: PM000796-00 Combogesic 500 mg-150 mg Pack Insert - UK fr Approval.pdf	
Source Envelope:	
Document Pages: 2	Signatures: 2
Certificate Pages: 4	Initials: 0
AutoNav: Enabled	Envelope Originator:
Envelope Stamping: Enabled	Brennan Bratchie
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	46 High Street
	Yatton, BS49 4HJ
	brennan@qp-services.com
	IP Address: 83.151.207.162


Record Tracking

Status: Original	Holder: Brennan Bratchie	Location: DocuSign
10/31/2023 3:24:27 AM	brennan@qp-services.com	

Signer Events

Brennan Bratchie
brennan@qp-services.com
Security Level: Email, Account Authentication (None)

Signature

DocuSigned by:

3F56F95B997A497...

Signature Adoption: Uploaded Signature Image
Using IP Address: 83.151.207.162

Timestamp

Sent: 10/31/2023 3:24:57 AM
Viewed: 10/31/2023 3:25:49 AM
Signed: 10/31/2023 3:26:34 AM
Freeform Signing

Electronic Record and Signature Disclosure:

Accepted: 10/31/2023 3:25:49 AM
ID: 452a4c02-008c-4ac2-80b3-c89391c85b6a

In Person Signer Events**Signature****Timestamp****Editor Delivery Events****Status****Timestamp****Agent Delivery Events****Status****Timestamp****Intermediary Delivery Events****Status****Timestamp****Certified Delivery Events****Status****Timestamp****Carbon Copy Events****Status****Timestamp****Witness Events****Signature****Timestamp****Notary Events****Signature****Timestamp****Envelope Summary Events****Status****Timestamps**

Envelope Sent	Hashed/Encrypted	10/31/2023 3:24:58 AM
Certified Delivered	Security Checked	10/31/2023 3:25:49 AM
Signing Complete	Security Checked	10/31/2023 3:26:34 AM
Completed	Security Checked	10/31/2023 3:26:34 AM

Payment Events**Status****Timestamps****Electronic Record and Signature Disclosure**

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Matt Parfitt (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Matt Parfitt:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: matt@qp-services.com

To advise Matt Parfitt of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at matt@qp-services.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Matt Parfitt

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to matt@qp-services.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Matt Parfitt

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to matt@qp-services.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Matt Parfitt as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Matt Parfitt during the course of your relationship with Matt Parfitt.